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Abstract
Background: There is a need for novel approaches to the treatment of stimulant abuse and dependence. Clinical
data examining the use of exercise as a treatment for the abuse of nicotine, alcohol, and other substances suggest
that exercise may be a beneficial treatment for stimulant abuse, with direct effects on decreased use and craving.
In addition, exercise has the potential to improve other health domains that may be adversely affected by
stimulant use or its treatment, such as sleep disturbance, cognitive function, mood, weight gain, quality of life, and
anhedonia, since it has been shown to improve many of these domains in a number of other clinical disorders.
Furthermore, neurobiological evidence provides plausible mechanisms by which exercise could positively affect
treatment outcomes. The current manuscript presents the rationale, design considerations, and study design of the
National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) CTN-0037 Stimulant Reduction Intervention
using Dosed Exercise (STRIDE) study.
Methods/Design: STRIDE is a multisite randomized clinical trial that compares exercise to health education as
potential treatments for stimulant abuse or dependence. This study will evaluate individuals diagnosed with
stimulant abuse or dependence who are receiving treatment in a residential setting. Three hundred and thirty
eligible and interested participants who provide informed consent will be randomized to one of two treatment
arms: Vigorous Intensity High Dose Exercise Augmentation (DEI) or Health Education Intervention Augmentation
(HEI). Both groups will receive TAU (i.e., usual care). The treatment arms are structured such that the quantity of
visits is similar to allow for equivalent contact between groups. In both arms, participants will begin with
supervised sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be
conducted as one-on-one (i.e., individual) sessions, although other participants may be exercising at the same time.
Following the 12-week acute phase, participants will begin a 6-month continuation phase during which time they
will attend one weekly supervised DEI or HEI session.
Clinical Trials Registry: ClinicalTrials.gov, NCT01141608
http://clinicaltrials.gov/ct2/show/NCT01141608?term=Stimulant+Reduction+Intervention+using+Dosed
+Exercise&rank=1
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Background
There is a need for novel approaches to the treatment of
stimulant use disorders. Stimulant use disorders are
chronic, relapsing illnesses with few highly efficacious
treatments [1]. In control conditions (Treatment as Usual;
TAU) for substance use disorders, typically only about
13% of participants achieve abstinence [1]. Abstinence
rates for treatments designed to augment TAU vary widely
- ranging from 14-60%[2-5] - depending on the outcome
variable and primary endpoint selected. Currently, the best
treatments for cocaine and other stimulant use disorders
are behavioral treatments that combine cognitive beha-
vioral therapy (CBT) with contingency management [1,6].
However, it is clear that new treatments are still needed
for stimulant abuse and dependence.
Exercise is a promising new treatment option for stimu-
lant abuse and dependence. Randomized controlled trials
examining exercise to improve outcomes in smoking ces-
sation provide some of the most convincing support for
investigating the use of exercise (and most frequently,
vigorous intensity exercise) to improve outcomes in stimu-
lant abuse [7-11]. While randomized controlled trials in
patients abusing substances other than tobacco or alcohol
are not yet available, some studies report benefits such as
increased abstinence and reduced substance use that are
associated with the use of exercise [12-14]. Furthermore,
in a post hoc analysis of data from 187 participants in two
randomized trials evaluating contingency management for
the treatment of substance abuse disorders [15,16], partici-
pants who reported engaging in exercise-related activities
had an increased length of abstinence [17]. In a recent
pilot study of moderate-intensity aerobic exercise added to
treatment for 16 individuals with substance dependence,
percent days abstinent significantly increased from base-
line, and 66.7% of the sample had been continuously absti-
nent at the end of a 12-week intervention [18].
Exercise may also provide additional health benefits
and functional improvements for stimulant users. Exer-
cise has been shown to reduce depression and anxiety
during alcohol treatment [19-21], as well as smoking ces-
sation treatment [22-24]. Exercise is also associated with
improved quality of life [25] and sleep [26], both of
which are disrupted by stimulant use even after absti-
nence is achieved [27,28]. In addition, concern about
weight gain following cessation of abused substances may
increase risk of substance use relapse [29-31], and regular
exercise may prevent or reduce post cessation weight
gain. Furthermore, Greenwood et al. [32] has demon-
strated improvements in hippocampal-dependent contex-
tual learning and memory in rats with exercise. Similar
results have been found for exercise-induced hippocam-
pal neurogenesis and improvements in spatial memory in
rats and mice [33-35]. Since substance abuse has been
associated with memory impairments that are influenced
by hippocampal function [36], exercise may be associated
with improved memory for these individuals.
Exercise may improve outcomes through any of several
possible mechanisms. Exercise is likely to impact the
underlying biology of addicted persons, as well as act as a
behavioral treatment intervention. Summarizing studies
of the effect of exercise on neurotransmitters [37] con-
clude that exercise results in changes in synthesis and
metabolism within central dopaminergic, noradrenergic,
and serotonergic systems, all of which are implicated in
addiction. Additional biological effects of exercise may
include decreased reactivity to stress [38] and decreased
use of substances as a way of coping with stress [39].
Exercise-induced improvements in self-efficacy [40,41]
may be another mechanism for improving outcomes. It
has also been suggested that exercise may be a distraction
[42], allowing attention to be diverted from urges to use
substances [43] or a positive lifestyle change that can
substitute for use of substances [44,45].
The current paper provides a description of the design
of the Stimulant Reduction Intervention using Dosed
Exercise (STRIDE) study, a multisite randomized, con-
trolled trial aimed at comparing the augmentation of
treatment as usual with either an exercise or health edu-
cation intervention in a stimulant abusing population. If
exercise is found to improve outcomes for substance
use disorders, the public health significance would be
substantial. A novel, low cost treatment would be avail-
able for substance users that could assist with both
acute treatment and reducing long-term relapse.
There were several challenges in the design of such a
trial, such as: 1) determining the appropriate comparison
group, 2) selecting the appropriate primary outcome, and
3) selecting the appropriate setting for the conduct of the
study. These challenges were enhanced by the fact that
there are no standardized designs that have focused on
how best to assess the effects of augmentation treatments,
particularly those that take into account patients’ transi-
tion from residential to intensive outpatient and longer
term treatment. This problem is compounded by the fact
that there is no agreed upon single outcome to best assess
the effectiveness of a treatment for stimulant abuse [46].
This manuscript provides a general description of the
STRIDE trial and how the particular issues associated with
this type of study were addressed.
Methods/Design
Overview
STRIDE is designed to test the efficacy of exercise or
health education augmentation for the treatment of sti-
mulant abuse. This study will evaluate individuals diag-
nosed with stimulant abuse or dependence (cocaine,
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methamphetamine, amphetamine or other stimulant,
except caffeine or nicotine, as defined by the Diagnostic
and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision [DSM-IV-TR]) who are receiving
treatment in a residential setting. Three hundred and
thirty eligible and interested participants who provide
informed consent will be randomized to one of two
treatment arms: Vigorous Intensity High Dose Exercise
Augmentation (DEI) or Health Education Intervention
Augmentation (HEI). Both groups will receive TAU (i.e.,
usual care). The study intervention begins while partici-
pants are receiving treatment in a program with a resi-
dential stay. The treatment arms are structured such
that the quantity of visits is similar to allow for equiva-
lent contact between groups. In both arms, participants
will begin with supervised sessions 3 times per week
during the 12-week acute phase of the study. Supervised
sessions will be conducted as one-on-one (i.e., indivi-
dual) sessions, although other participants may be exer-
cising at the same time. Following the 12-week acute
phase, participants will begin a 6-month continuation
phase during which time they will attend one weekly
supervised DEI or HEI session. The study design is dis-
played in Figure 1. A Data and Safety Monitoring Board
assembled by NIDA approved the final study design and
will be providing ongoing monitoring throughout imple-
mentation of the trial.
Study Sites
This study is being conducted on the National Drug
Abuse Treatment Clinical Trials Network (CTN). Partici-
pating sites are CTN Community Treatment Programs
(CTPs) meeting site characteristics identified based on
the requirements of the study protocol [47]. Each site is
partnered with a Regional Research and Training Center
(RRTC), an academic institution led by a substance use
researcher. The RRTC helps guide the conduct of the
study at the site. The site characteristics include: 1) a
treatment program with a residential component and
length of stay generally between 21 and 30 days; 2) no
formal exercise program that includes more than an hour
a week of exercise, or willingness to exclude participants
from the program; 3) availability of community outpati-
ent treatment at or near the residential setting where the
study is located so that it is feasible for participants to
return to the study site to complete study activities for
the full 9 months of the study; 4) a sufficient number of
clients admitted to residential treatment per month who
might be eligible to participate in the study; and 5) ade-
quate space to accommodate study staff and activities.
Sites were selected in two groups based on survey
responses, phone interviews, and site visits. Four Wave 1
sites were identified and approved to begin the study
about 6 months earlier than the five Wave 2 sites. This
model allows for early identification and resolution of
any operational issues in the conduct of the study.
Aims
The primary aim of STRIDE is to compare percent days
of abstinence between the DEI and HEI groups based on
stimulant use during the 12-week acute phase. It is
hypothesized that DEI will be associated with signifi-
cantly greater (p < 0.05) percent days of abstinence than
HEI as measured by a corrected Timeline Followback.
Timeline Followback (TLFB)[48,49] is collected as
described by Sobell and with the aid of a Substance Use
Diary. Additionally, a urine drug screen is collected three
times per week to improve the accuracy of and correct
the self-report data from the TLFB at the time of data
analysis based on an algorithm [50].
Secondary aims of STRIDE are: 1) to compare time to
relapse (defined as second positive urine test [for stimu-
lants] and use of drugs (assessed via TLFB) between the
DEI and HEI groups; 2) to evaluate withdrawal symptoms
between the DEI and HEI groups; 3) to evaluate drug use
and related outcomes for other substances (categorized
as alcohol, cannabinoids, nicotine, opioids, or sedative/
hypnotic/anxiolytics); 4) to compare time to dropout
from substance abuse treatment between the DEI and
HEI groups; 5) to evaluate drug use and related outcomes
during the entire course of the study (i.e., randomization
to 9 months). Finally, as an exploratory aim, we will
attempt to determine if there are additional health bene-
fits to using exercise augmentation in the treatment of
substance use disorders. Specifically, we will examine the
effects of exercise augmentation on sleep, cognitive func-
tion, mood, quality of life, anhedonia, and weight gain
compared to HEI over the course of the 12-week acute
phase and over the 9-month study period.
Eligibility Criteria
Participants will be ambulatory males or females, ages 18
to 65, who have been admitted to substance use treat-
ment in a participating residential setting. Participants
must have self-reported stimulant drug use (cocaine,
methamphetamine, amphetamine, or other stimulant,
excluding caffeine and nicotine) within the 30 days prior
to admission for residential treatment and meet DSM-
IV-TR criteria for substance abuse or dependence for sti-
mulants within the last 12 months. They must receive
medical clearance through a protocol-defined maximal
exercise test (in accordance with American College of
Sports Medicine (ACSM) guidelines [51]) and a careful
history and physical examination from protocol-approved
medical personnel. Participants must have the ability to
understand and willingness to provide written informed
consent. Persons meeting the following criteria will be
excluded from participation: general medical condition(s)
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that contraindicate exercise, opiate dependence, psycho-
sis, or other psychiatric issue(s) that poses a safety risk,
pregnancy, or concomitant treatment with beta blockers
or opioid replacement therapy (e.g., methadone or
bupenorphine).
Exercise Intervention
Intervention Overview
Participants in DEI will perform their exercise sessions
on a Life Fitness 95T-seriesTreadmill (Schiller Park, IL).
Prescribed exercise doses and intensities will be ramped
over the initial 3 weeks of the study to allow for a gradual
familiarization to the study protocol and the accompany-
ing physical demands (see Table 1). Exercise intensity
will be based on a percentage of the maximum heart rate
(HR) achieved during the baseline maximal exercise test.
The 12 kilocalories*kilogram of bodyweight-1 * week-1
(KKW) weekly exercise dose was chosen to approximate
public health dose guidelines http://www.health.gov/
paguidelines (i.e., approximately 30-50 min, 3-5 days per
week). Participants will be scheduled to complete their
weekly exercise dose over three exercise sessions. How-
ever, additional exercise sessions can be scheduled for
those needing more than three sessions per week to
achieve their target dose.
Exercise Sessions
During the supervised exercise sessions, participants will
perform an active warm-up for 5 minutes prior to initia-
tion of the exercise prescription. Polar RS 400 HR moni-
tors (Kempele, Finland) will be used to continuously
monitor participants’ heart rate (HR) throughout the
Figure 1 STRIDE Design Schematic.
Table 1 Ramping Schedule for Exercise Dose and
Intensity
Week No. Exercise Dose
(KKW)
Exercise Intensity
(% HRmax)
1 6 50 - 60
2 9 60 - 70
3 - 36 12 70 - 85
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exercise session to ensure that they are within their tar-
get HR zone (i.e., 70-85% of an individual’s HRmax).
Typically, participants can achieve a HR of 70-85% by
either walking briskly at an incline or by running at
zero incline. The speed and/or grade of the treadmill
will be continually adjusted to maintain participant HR
within the target HR zone while allowing the partici-
pants some flexibility in customizing their exercise ses-
sion. A global Rating of Perceived Exertion (RPE),
assessed using Borg’s RPE scale, will be taken at the
conclusion of each exercise session. At the completion
of the exercise session, participants will perform an
active cool down (0 grade and 50-70% of speed) until
their HR returns to within 15% of their resting value.
Participants will then be led through a 5-10 minute
stretching routine.
During the continuation phase, participants will com-
plete one supervised exercise session per week at the
CTP exercise facility with the remainder of their exercise
dose to be completed in unsupervised exercise sessions.
Exercise Facilitators will aid the participant in identifying
a safe location for completing their unsupervised
sessions, scheduling these sessions, and planning other
practical concerns related to engaging in exercise during
the continuation phase. Participants will also receive
assistance in developing measured exercise courses to
allow for estimates of time and distance covered at each
unsupervised session. Participants will record a global
RPE score at the end of each unsupervised exercise
session.
Exercise Safety
Those who are not safe to exercise, including those with
greater than Stage 1 hypertension will not be rando-
mized. Prior to each exercise session, participants will sit
undisturbed for 5 minutes before assessment of their
resting heart rate and blood pressure (BP). If a partici-
pant’s resting HR is ≥ 100, it will be re-measured after an
additional 5-minute rest period. If a participant’s resting
HR remains ≥ 100, the exercise session will be resched-
uled for another day. Likewise, if a participant’s resting
BP is ≥ 160/100, it will be re-measured after an additional
5-minute rest period. If a participant’s resting BP remains
≥ 160/100, the exercise session will be rescheduled for
another day. During the session, BP will be assessed after
5 minutes to monitor for adverse responses to the onset
of the exercise. BP will continue to be monitored if an
exaggerated acute response is observed (i.e., SBP > 200
mmHg). The exercise session will be halted if an extreme
BP response (SBP > 250 mmHg or remains unchanged
despite an increase in workload, or DBP increase >
15 mmHg) is observed. Following the cool down, a final
BP will be taken before the participant is cleared to leave
the facility. Guidelines are also present for referral to
appropriate medical care and additional physician clear-
ance based on blood pressure readings.
Health Education Intervention
The health education intervention is structured to provide
equivalent contact time to that of the exercise intervention.
During the acute phase, participants will complete three
supervised sessions per week. Visits will be weekly during
the continuation phase. During HEI sessions participants
will view educational items such as didactic presentations,
readings, Web sites, and audio or video materials. Instruc-
tional topics include areas such as healthy eating, preven-
tive health care and recommended health screenings,
accessing health care resources, and other health-related
topics that are relevant to adults with substance use disor-
ders. Exercise and topics central to substance use treatment
(e.g., coping with cravings, relapse prevention) are not
included to prevent intervention contamination and not
change TAU, respectively. Participants will be encouraged
to suggest topics of interest to help maintain their involve-
ment and engagement in the sessions throughout the dura-
tion of the study. The HEI program is modeled after
similar programs that have been used successfully as
control groups in clinical trials examining exercise as an
intervention [7,52,53].
Behavioral Adherence Program
A comprehensive behavioral adherence approach to facil-
itating and monitoring fidelity to exercise dose has been
developed by our team through our work in conducting
exercise interventions in depressed populations [54].
Individuals in both treatment arms will receive adherence
support through the behavioral adherence program. This
program serves to: 1) provide necessary tools and support
for participants to help them successfully complete the
intervention and 2) allow for individualized monitoring
to address person-specific adherence issues and barriers
to the assigned intervention. The program includes:
1) multidisciplinary psychoeducation about adherence,
2) intervention skills training, 3) weekly intervention pre-
scription provided via the study Web site, 4) self-moni-
toring of intervention adherence and performance,
5) adherence feedback from study Web site and interven-
tion facilitator, and 6) weekly intervention planning (indi-
vidually-tailored plan). Facilitators assist participants each
week throughout the study with planning and adhering
to a schedule for completion of their intervention ses-
sions. Facilitators proactively review both potential and
identified barriers to adherence (e.g., transportation,
work schedules) and discuss possible solutions to work
around these barriers (e.g., planning bus routes, provid-
ing flexible appointment times). Participants work with
facilitators to use the study Web site during supervised
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sessions and are able to continue using the Web site dur-
ing home-based sessions if they have access to the
Internet.
Study Assessments
Table 2 summarizes the assessments used throughout
the study, their main purpose, their frequency of admin-
istration, and psychometric properties if available.
Diagnostic and Screening Assessments
At screening, standard demographic information will be
collected from all participants (e.g., gender, race, ethnicity,
etc.). Contact information will be obtained and updated
monthly and additionally as needed. DSM-IV-TR alcohol
and substance abuse and dependence will be assessed with
the substance use modules of the World Health Organiza-
tion (WHO) Composite International Diagnostic Interview
(CIDI) (Version 2.1)[55,56]. Additional DSM-IV Axis I
diagnostic information will be obtained using the MINI
International Neuropsychiatric Interview (MINI)[57].
Medical Evaluation
Medical history will be obtained using a self-report medi-
cal history form designed to collect information about his-
tory and/or treatment of medical conditions, such as heart
disease, high blood pressure, diabetes, and cancer. The
form also assesses allergies, past surgeries, tobacco and
alcohol use, family history of medical conditions, medical
symptoms over the past 30 days, and prior and concomi-
tant medications. Additionally, participants will complete
the Self-Administered Comorbidity Questionnaire (SCQ)
[58] and the Physical Activity Readiness Questionnaire
(PAR-Q)[59]. Medical personnel will conduct a medical
history and physical exam, and laboratory tests (chemistry,
hematology, lipid profile, and urinalysis) will be obtained
as part of the medical screening process.
Maximal exercise testing will be conducted during the
screening process to examine cardiorespiratory responses
in order to rule out ischemic response to exercise (with
its implications of cardiovascular disease), to identify par-
ticipants for whom exercise might be hazardous, and to
provide data for the exercise prescription. The test will
be repeated at the end of the 12-week acute phase (or
during an early termination visit). A trained technician
will process the test data and a report will be generated
that contains the following information: 1) participant’s
symptoms before, during, and after testing; 2) maximal
heart rate achieved and percent of predicted maximal
heart rate achieved; 3) time on treadmill and estimated
maximal metabolic equivalent (METS) achieved; and 4)
ECG interpretation. A designated medical staff member
will be responsible for reviewing the participant’s medical
history and evaluating results from the medical exam,
maximal testing, and lab results to determine whether or
not the participant is medically cleared to exercise.
Eligible participants complete a comprehensive base-
line assessment. Since there are numerous baseline
assessments, these may be distributed over more than
one day if necessary. The frequency and type of ongoing
assessments are equivalent in both groups, with the
exception of blood pressure and heart rate obtained for
exercise participants prior to every supervised exercise
session. Descriptions of ongoing study assessments are
described by category below (as well as in Table 2).
Substance Use and Treatment Assessments
The Timeline Followback [48,49] and Substance Use
Diary (SUD) will be used to acquire information on alco-
hol and drug use, including cocaine and other stimulants.
The TLFB is a semi-structured interview that uses a
calendar to prompt participants to provide retrospective
estimates of their daily drug use over a specified period
of time that can vary up to 12 months before the inter-
view date. The measure provides prompts to facilitate
accurate recollection of use behavior. The SUD, a pocket
calendar given to participants at the beginning of the
study to prospectively record substance use, will assist
with accurate recall when completing the TLFB at each
study visit.
Qualitative urine drug screens (UDS) will be conducted
at baseline, three times a week in the first 12 weeks, and
once a week in the subsequent 6 months. The screen will
test for the following substances: marijuana, cocaine, opi-
ates, amphetamine, methamphetamine, benzodiazepines,
barbiturates, methadone, methylenedioxymethampheta-
mine (MDMA, Ecstasy), and oxycodone. UDSs will also be
used to corroborate information on the TLFB.
The Addiction Severity Index-Lite (ASI-Lite) will be
administered by research staff to examine multiple
domains that are commonly affected by substance use,
including medical, employment/self-support, alcohol/drug
use, legal status, family/social, and psychiatric status [60].
Stimulant craving (cocaine, methamphetamine, and other
stimulants) will be assessed using the Stimulant Craving
Questionnaire-Brief (STCQ-Brief; adapted from Sussner et
al. [61] and derived from the 10-item Cocaine Craving
Questionnaire-Brief and the original 46-item Cocaine
Craving Questionnaire-Now [62]). Signs and symptoms of
stimulant (cocaine, methamphetamine, and other stimu-
lants) abstinence will be evaluated using the Stimulant
Selective Severity Assessment (SSSA; adapted from Kamp-
man et al. [63]). Baseline nicotine dependence will be eval-
uated using the Fagerstrom Test for Nicotine Dependence
(FTND)[64,65] and number of cigarettes smoked per day
will be captured on the TLFB.
Mood and Functional Measures
Symptoms of depression will be measured by the Quick
Inventory of Depressive Symptomatology - Clinician
Rated version (16-item)[66-70], and the Snaith-Hamilton
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Table 2 STRIDE Assessments
Assessment Frequency Purpose and Psychometrics
Diagnostic and Screening Measures
Demographics Form Screen To gather basic demographic information.
Composite International Diagnostic
Interview (CIDI) (Modules A, J, & L)
Screen To obtain substance use diagnoses. Tests of the reliability of the
CIDI-SAM based on DSM-IV diagnoses for cocaine dependence
compared to SCID interviews done by trained clinicians, had
percent agreement of 82.6%, with kappa = 0.61. With specific
criteria for the diagnosis, kappas ranged between 0.68 and 0.55.
Mini International Neuropsychiatric
Interview (MINI)
Screen To identify Axis I psychiatric diagnoses (excluding substance use
disorders). In comparison to the Structured Clinical Interview for
DSM-IV Disorders (SCID-P), kappa values were good (only one
diagnosis < .50), specificities and negative predictive values were
.85 or higher across diagnoses, and in general, sensitivity was .70
or higher [113].
Locator Form Screen, monthly To obtain contact information for each participant.
Prior and Concomitant Medications Screen, weekly To assess prescribed medications taken by the participant.
Self-Administered Comorbidity
Questionnaire (SCQ)
Screen To assess the presence of medical problems, their severity, and
whether or not the condition limits functioning. An intraclass
correlation coefficient of 0.94 shows good test-retest reliability and
is comparable to the Charlson Index intraclass correlation
coefficient of 0.92.
Physical Activity Readiness
Questionnaire-Revised (PAR-Q)
Screen To determine whether a person needs to consult with their
physician prior to engaging in an exercise program.
Medical History- Self-report Form Screen To obtain information that will facilitate the conduct of the
physical exam, clinician-rated medical history, and maximal
exercise test.
Maximal Exercise Test Screening
Questions
Screen To aid the medical personnel in ensuring that it is safe for the
participant to undergo the maximal exercise test
Maximal Exercise Testing Screen, week 13 To examine cardiorespiratory responses in order to rule out
ischemic response to exercise, to identify participants for whom
exercise might be hazardous, and to provide data for the exercise
prescription.
Physical Exam/Medical History Screen To provide clearance for exercise.
Laboratory Tests Screen To provide clearance for exercise.
Substance Use and Treatment Assessments
Timeline Followback (TLFB)*
*Primary outcome measure
Screen, 3X/wk for 1st 3 months, 1X/wk for
next 6 months
To quantify days of substance use for calculation of primary
outcome (percent days abstinent). The TLFB has been shown to
have high test-retest reliability (ICC values ranging from 0.70 to
.94, with all p < 0.001), good convergent and discriminate validity,
and acceptable agreement between the TLFB and urine drug
screens (Yule’s Y of 87 or greater for amphetamines and cocaine)
[114].
Urine Drug Screen (UDS) Baseline, 3X/wk for 1st 3 months, 1X/wk
for next 6 months
To test for substance use and to inform TLFB.
Stimulant Craving Questionnaire-
Brief (STCQ-Brief)
Baseline, weekly To assess current craving for stimulants. The CCQ-Brief, from which
the STCQ-Brief is adapted, has high internal consistency, with
Cronbach’s alpha ranging from 0.87 [115] to 0.90 [61]. The
instrument also has good construct validity and has shown to
correlate well with other craving measures [115].
Stimulant Selective Severity
Assessment (SSSA)
Baseline, weekly To assess signs and symptoms of stimulant abstinence. The
Cocaine Selective Severity Assessment, from which the SSSA is
adapted, has been shown to have good inter-rater reliability
(correlation coefficient = 0.92, p < 0.001) and internal consistency
(Cronbach’s alpha = 0.80).
Addiction Severity Index-Lite (ASI-
Lite)
Baseline, weeks 13, 25, 37 To assess common problems associated with drug use. The CTN
version is similar to the ASI-Lite-Veterans Administration (ASI-L-VA)
and should have similar psychometric characteristics. Specifically,
intraclass correlations between the ASI fifth edition (ASI-5) and
ASSI-L-VA are 0.79 for alcohol, 0.79 for drug, 0.85 for legal, 0.46 for
family/social, and 0.53 for psychiatric [116].
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Pleasure Scale (SHAPS)[71] will be used to measure
anhedonia. Suicidality and related symptoms will be
evaluated throughout the study using the Concise
Health Risk Tracking - Self-Report (CHRT-SR), and the
Concise Associated Symptoms Tracking - Self-Report
(CAST-SR).
Table 2 STRIDE Assessments (Continued)
Fagerstrom Test for Nicotine
Dependence (FTND)
Baseline To assess dependence on nicotine. The FTND has shown
acceptable internal consistency (Cronbach’s alpha of 0.61) and
correlates significantly with other measures of smoking
consumption.
Treatment as Usual (TAU) Tracking
Form
Baseline, weekly To assess the participant’s treatment for substance abuse within
the past week.
Measures of Mood, Sleep and Anhedonia
Quick Inventory of Depressive
Symptomatology- Clinician rated
version (QIDS-C16)
Baseline, weekly To assess severity of depression-specific symptoms. The internal
consistency coefficient is high (Cronbach’s alpha of 0.90)[70]. It
also has good concurrent validity, with correlations between the
QIDS and the 17-item Hamilton Rating Scale for Depression
ranging between .86 and .93. It also has been shown to have
good inter-rater reliability with a kappa of .85.
Concise Health Risk Tracking- Self-
report (CHRT-SR)
Baseline, weekly To assess suicidality and related thoughts and behaviors. The
CHRT-SR has good internal consistency (Cronbach’s alpha of 0.78).
Concise Associated Symptoms
Tracking- Self-report (CAST-SR)
Baseline, weekly To assess symptoms related to suicidal thoughts and behaviors.
The internal consistency coefficient for the CAST-SR is good
(Cronbach’s alpha of 0.77).
Snaith-Hamilton Pleasure Scale
(SHAPS)
Baseline, monthly To measure anhedonia, the inability to experience pleasure. The
SHAPS has adequate construct validity, satisfactory test-retest
reliability [117], and high internal consistency (Cronbach’s alpha of
0.94)[117].
Psychosocial Assessments
Short-Form Health Survey (SF-36) Baseline, monthly To assess quality of life and general health. Internal consistency
reliability coefficients for the SF-36 are high (all greater than 0.80).
Test-retest coefficients range from 0.43 to 0.90 for a 6-month
interval and from 0.60 to 0.81 for a 2-week interval. The SF-36 has
been shown to correlate moderately well with other health
measures.
Quality of Life Enjoyment and
Satisfaction Questionnaire Short
Form (Q-LES-Q-SF)
Baseline, monthly To evaluate general life enjoyment and satisfaction. Test-retest
reliability for the Q-LES-Q-SF has been shown to be .86 [118] and
internal consistency (Cronbach’s alpha) has been shown to range
from .86 to .90 [118,119].
Pain Frequency, Intensity and
Burden Scale (P-FIBS)
Baseline, monthly To evaluate the frequency, intensity, and burden of pain over the
past week, as well as usage of pain medication to manage pain.
Cognitive Function Assessments
Wechsler Test of Adult Reading
(WTAR)
Baseline To assess pre-morbid intelligence. The WTAR has been established
to be a reliable and valid assessment of pre-morbid intelligence. It
has been normed with the Wechsler Adult Intelligence Scale
(WAIS-III) and the Wechsler Memory Scale (WMS-III).
MGH Cognitive and Physical
Functioning Questionnaire (CPFQ)
Baseline, monthly To assess physical well-being and cognitive and executive
dysfunction. The CPFQ has been shown to have high internal
consistency with a Cronbach’s alpha of 0.90 and test-retest
reliability (0.83, p < 0.001)[120].
Stroop Color and Word Test (Stroop) Baseline, weeks 13, 37 To measure attention response inhibition.
Physiological Measures
Physiological Measures Baseline, monthly (height once at
baseline, weight weekly)
To measure height, weight, body mass index (BMI), and waist
circumference
Exercise Readiness Form Baseline, each supervised exercise session
(3X/wk for 1st 3 months, 1X/wk for next 6
months)
To measure resting heart rate and blood pressure for those in the
exercise condition in order to evaluate safety for exercise.
Retention
Treatment Participation
Questionnaire (TPQ)
Baseline, weekly To assess participant’s likelihood of remaining in treatment.
Trivedi et al. Trials 2011, 12:206
http://www.trialsjournal.com/content/12/1/206
Page 8 of 15
Psychosocial assessments will include the Quality of
Life Enjoyment and Satisfaction Questionnaire Short
Form (Q-LES-Q-SF [72]), the Short-Form Health Survey
(SF-36 [73,74]), and the Pain Frequency, Intensity and
Burden Scale (P-FIBS). Assessments of cognitive func-
tion will include the Stroop Color and Word Test
[75,76], a measure of attention response inhibition, and
the MGH Cognitive and Physical Functioning Question-
naire (CPFQ [77]), a measure of subjective cognitive
function. The Wechsler Test of Adult Reading (WTAR
[78]) will be administered at baseline to assess premor-
bid intelligence.
Fitness and Physiological Measures
Physiological measures include height, weight, body mass
index (BMI), and waist circumference. For those partici-
pants in the exercise intervention, resting heart rate and
blood pressure will be obtained prior to each exercise
session using the Exercise Readiness Form in order to
evaluate safety to exercise. Resting heart rate and blood
pressure will be obtained for all participants during the
maximal exercise test. The maximal exercise will be
repeated at week 13 to assess change in fitness.
Retention
The Treatment Participation Questionnaire (TPQ), a five-
item self-report that assesses the participant’s likelihood of
remaining in treatment for substance abuse and continu-
ing to attend study visits, will be administered at baseline
and then weekly thereafter. Since this study is designed as
an intent-to-treat study, subjects will be encouraged to
complete assessments regardless of their status in their
treatment programs or their engagement in the study
intervention.
Analytic Methods
The primary analysis will compare the primary outcome
between the two treatments taking into account possible
variability in the overall level of abstinence between sites.
More specifically, we use a mixed normal model with a
fixed treatment effect and random terms for site and
error. The model considers treatment effect to be the
same in each site. P-value less than 0.05 will be considered
statistically significant. The assumed treatment effect
μVIHD-μHEC is 0.15. The error standard deviation s is con-
sidered to be in the range between 0.40 and 0.45, and
abstinence status within participant is assumed to be cor-
related across days. The primary endpoint will be analyzed
on an intent-to-treat basis, meaning that participants’ data
will be analyzed according to the group they were rando-
mized to, regardless of the subsequent sequence of events
(e.g., noncompliance to the intervention).
Even though the overall level of outcome may differ
across sites (i.e. ssite > 0), the primary analysis removes
this variation by adjusting for site in the model. Hence,
initial sample size computations are based on value of
error standard deviation s and the sample size estimates
are based on a two sample t-test formula. A treatment
effect that varies across sites may contribute additional
variation and simulations with primary analysis per-
formed for each simulation were used to investigate this
possibility. Based on these simulations, and as an addi-
tional precaution, we increased initial sample size by 10%
to attempt to take into consideration potential treatment
effect variability. Based on these considerations, we
proposed the trial to enroll 330 participants. Clearly, the
proposed sample size depends on accurate estimation of
variability s. We propose to reassess this variability
midway through the study, i.e., after approximately 165
participants have enrolled and completed the acute phase
of the trial, and may readjust needed sample size if the
variance assumption proves incorrect.
Rationale for Key Study Design Choices
Population
For this study, we chose to specifically evaluate individuals
with stimulant abuse or dependence. This decision was
made in order to reduce heterogeneity of the sample with
respect to drug use, since this is an early efficacy trial with
a new intervention in a substance using population.
Setting
This study is designed to start while participants are in a
residential setting and continues as participants transition
into outpatient and other community care. Starting treat-
ment in the residential setting was chosen to maximize
the availability of participants to be present for the initial
evaluation and training of the exercise intervention. Given
the dose and intensity of exercise selected for this study, it
is critical that participants be consistent in attending
supervised sessions, particularly as they are first learning
how to implement the exercise protocol, how to use all
related equipment, and how to collect and record all exer-
cise-related data. A transition to outpatient care is a typical
occurrence in the treatment of substance use disorders.
This study is designed to evaluate participants as they
transition to the next phase of care. While the decision to
begin in a residential setting could result in somewhat less
generalizability of findings, since this is an early efficacy
study, we determined that it was more important to
ensure that our study population was present to receive
sufficient training and supervision in the exercise interven-
tion and to maximize adherence during this time.
Study Duration
The total duration of participation in STRIDE is 9
months. A 6-month duration for the continuation phase
was selected because we would like to see if there is a
sustained response to the exercise intervention. In most
chronic diseases, longer-term outcomes are best seen in
the 6 months following acute phase intervention.
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Exercise Intervention
One of the major hurdles in successfully conducting
exercise trials has been the inconsistency of type, dose,
and intensity of exercise achieved. We elected to define
exercise type, dose and intensity in this study to mini-
mize variability and to achieve pre-specified targets for
both dose and intensity.
Type
We selected the use of aerobic exercise in this trial.
While there is some evidence that other types of exer-
cise (e.g., weight training) may be beneficial to indivi-
duals with other disorders, such as depression, the
preponderance of existing evidence supports the use of
aerobic exercise. Furthermore, aerobic exercise has been
used in previous interventions involving substance abuse
disorders [7-11,18].
Dose
A 12 KKW dose of exercise was selected for this study
for the following reasons: 1) it is consistent with U.S.
2008 Physical Activity Guidelines http://www.health.gov/
paguidelines, as well as prior recommendations from
groups such as the Centers for Disease Control and Pre-
vention and ACSM [79-83], the NIH Consensus panel
[45,79,80,82-86], and the U.S. Surgeon General (U.S.
Department of Health and Human Services [87]); 2) it
has been used in previous studies involving physical
activity interventions in smokers [7,9], and in other disor-
ders such as depression [54,88-91], it is consistent with
doses associated with biological changes that we
hypothesize will impact stimulant use such as alterations
of the serotonergic [92-94] and endocannabinoid systems
[95], attenuated stress responses [96,97], and increases in
release of BDNF [98].
Intensity
An intensity range of 70-85% of an individual’s HRmax was
selected for this study. This intensity is above the sug-
gested minimum intensity of 50% of HRmax and within the
currently recommended training intensity guidelines for
producing physiological adaptations and benefits [51].
Although higher exercise intensities may produce greater
changes in outcomes at a constant dose, for this efficacy
trial we want to be certain that we are well within standard
exercising ranges for both dose and intensity. By selecting
a range of 70-85% of HRmax, we have allowed for some
exercising flexibility to increase comfort, while ensuring
that all participants are exercising above the minimum
recommended threshold.
Alternatively, we could have allowed participants to
select their own exercise intensity (i.e., self-selected
intensity based on rating of perceived exertion) as long as
they achieved the target dose. While this approach would
allow significantly greater flexibility for participants, it
would likely lead to greater variations in exercise inten-
sity. Another alternative would be to have a fixed exercise
intensity (i.e., 80% HRmax) to maximize the standardiza-
tion of the exercise intervention. However, a fixed inten-
sity would allow little flexibility for participants to find a
comfortable exercise level and may, therefore, result in
poor adherence and increased drop-outs.
Frequency
In this study, we recommend that participants complete
their prescribed weekly exercise dose over three exercise
sessions per week. However, we will allow up to two
additional sessions per week in order to accommodate
variations in baseline fitness levels. Individuals who are
more unfit will have a relatively low caloric expenditure
rate when exercising within their relative intensity range
(as demonstrated by elevated HRs at low treadmill set-
tings). This will require them to exercise for a greater
duration to achieve their weekly exercise dose than indi-
viduals who have higher baseline fitness levels. For exam-
ple, a participant exercising at 70% of their HRmax might
require 150 min/week (50 min/session for three sessions/
week) to achieve the 12 KKW dose, whereas a less fit par-
ticipant might require 240 min/week to achieve the same
12 KKW dose due to differences in exercise efficiency
and their individual responses to exercise. Therefore, it
benefits the second participant to divide their exercise
dose among four or five sessions, thereby increasing the
feasibility of completing each exercise session and achiev-
ing the weekly exercise dose.
Control Group
A health education intervention attention control group
was selected so that the effect of the exercise intervention
could not be attributed to the additional contact associated
with it. HEI has been established as an ineffective, yet
attentionally equivalent control condition in studies of
exercise and it has been used successfully [7,52,53,99,100]
and with good adherence by members of our study Proto-
col Development Team (Drs. Marcus, Church, Nunes and
Blair). Their use of HEI as a control condition and the
knowledge gained from their experience increases the like-
lihood that participants randomized to this arm of the
study will find this intervention acceptable. Participants
will be recruited to a “health intervention study”, one arm
of which is exercise, and the other health education, so
that HEI is not described as a control condition. While it
is true that participants will know their group assignment,
this has not been problematic in other studies using HEI
controls and there has not been differential attrition (i.e.,
Marcus et al. [7,10]). Participants in the HEI group will be
able to participate in selecting the material that is dis-
cussed in order to help maintain interest. Furthermore,
they will be monitored similarly to DEI participants, and
they will receive the same behavioral intervention strate-
gies as DEI participants in order to maximize adherence.
All attempts will be made to address barriers to retention
Trivedi et al. Trials 2011, 12:206
http://www.trialsjournal.com/content/12/1/206
Page 10 of 15
in the control condition, as in the exercise intervention.
HEI, as opposed to TAU alone, is also intended to ensure
continued participant engagement in the study and thus
minimize dropouts that might occur if attention in the
two groups were not equivalent. Other possible active con-
trol conditions (e.g., resistance training, relaxation, yoga,
or meditation) have the potential for efficacy, and in fact
some have shown efficacy both in substance use and in
other disorders (e.g., depression [101]). Thus, the use of an
active comparator would make it difficult to see a treat-
ment effect, so these alternative active control conditions
are not ideal comparators for an efficacy study of exercise.
Primary Outcome
The rationale for the outcome for the current study design
was driven by the desire to provide a meaningful clinical
outcome that would allow for the ready comparison of the
effectiveness of this treatment. In addition, it was impor-
tant that this outcome be suitable for an intent-to-treat
study such that all available data could be utilized for ana-
lysis. We decided upon an approach that integrates the
strengths of multiple measures and allows for data collec-
tion over an extended time period [46]. We chose to assess
percent days abstinent as measured by self-report using
the Timeline Followback. Some studies have shown that
this approach has been shown to correlate well with objec-
tive measures of use such as urine drug screen [102-104].
Disadvantages of the TLFB include potential inaccuracy
due to memory errors and bias and deliberate and denial-
based distortions of reported substance use. As a result,
two additional tools have been added to the data collection
process. The Substance Use Diary, which will aid with
recall during the TLFB assessment, has been shown to
improve the accuracy of the TLFB [105]. The diary can be
completed in real time in between study visits to help par-
ticipants maintain an accurate accounting of their usage of
stimulants, and will be particularly helpful in situations
where missed visits occur that result in greater amounts of
time to recall. Finally, to further improve the validity of
the TLFB, results will be confirmed with urine drug
screens collected 3 times per week and an algorithm will
be employed at the time of data analysis to reconcile dis-
crepancies between the TLFB and the urine drug screens
for the primary outcome.
Choice of the TLFB self-report measure was consis-
tent with several elements of our study design. Our
study intervention will be conducted over a 9-month
period during which time participants will not only tran-
sition from residential to outpatient treatment, but they
are expected to come to the study site 3 times a week
for the first 12 weeks and once a week for the following
24 weeks. Stimulant abusing patients are known to be
inconsistent in their attendance at treatment and study
visits [1]. This visit schedule therefore poses a serious
challenge to the use of a sole objective measure such as
UDS to define abstinent and non-abstinent days and
would likely result in considerable missing data. To
decrease the potential for missing data due to the short
half-life of stimulants, urine drug screens are often
obtained 3 times per week, but this frequency of assess-
ment would be very difficult to maintain over a 9-
month duration. The TLFB, on the other hand, allows
for data to be collected on all days, since the interviewer
prompts the participant to recall use for all days since
the last study visit.
Discussion
The STRIDE study aims to address the need for novel
treatments in stimulant use disorders. Studies demon-
strating the effectiveness of exercise in the treatment of
nicotine dependence and alcohol abuse suggest that exer-
cise augmentation of treatment as usual may be effica-
cious in increasing abstinence from stimulant use. The
potential effects of exercise on the underlying biological
mechanisms of stimulant addiction further support the
use of exercise in the treatment of stimulant abuse.
Finally, exercise may provide additional health benefits.
Stimulant use is detrimental to a number of health
domains including sleep [106,107], cognitive function
[36], and mood [108], while exercise results in improve-
ment of sleep quality [26,109], cognitive function [110],
and mood [89,94,111,112].
Several study design features help accurately assess the
efficacy and effectiveness of exercise augmentation for
stimulant abuse and dependence. First, the exercise type,
dose, and intensity are precisely defined to reduce varia-
bility. In addition, this dose of exercise is congruent with
current health recommendations and should be sufficient
to alter the hypothesized biological underpinnings of sti-
mulant dependence. Second, a comprehensive behavioral
intervention program will be implemented to facilitate
and monitor adherence to the two interventions. Facilita-
tors will provide participants with adherence feedback
and support the participant in addressing barriers to
adherence. Finally, the use of a health education interven-
tion control group will provide balanced facilitator atten-
tion across the two interventions. Health education
groups have proved to be ineffective in previous trials
[7,52,53,99], yet demonstrate high levels of adherence
and will provide equivalent facilitator contact.
This is one of the first studies conducted within the
CTN that is specifically designed as a first test of a new
intervention in a specific disorder. As such, it will not
only test the efficacy and effectiveness of this interven-
tion for stimulant abuse and dependence, but also pro-
vide information about conducting this type of study in
the context of a network of community treatment pro-
grams. Future studies are needed that evaluate the use
Trivedi et al. Trials 2011, 12:206
http://www.trialsjournal.com/content/12/1/206
Page 11 of 15
of exercise in the reduction in use of other illicit sub-
stances. In addition, new studies that examine the use of
exercise during different phases of treatment are needed.
For example, exercise may prove to be effective in redu-
cing symptoms of withdrawal but not in increasing
long-term abstinence, or vice versa. Finally, future stu-
dies should aim to identify the biological mechanisms
responsible for reductions in substance use.
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